#Germany #Fremont #Alamar Biosciences #DZNE #Rhineland Study

Alamar Biosciences Partners with DZNE

Alamar Biosciences has recently announced a significant strategic partnership with the German Center for Neurodegenerative Diseases (DZNE). This collaboration aims to advance understanding in the field of neurodegeneration through groundbreaking proteomic profiling techniques that will be applied in the extensive Rhineland Study.

The Rhineland Study is one of the world's largest and most comprehensive long-term cohort studies focused on aging and neurodegenerative diseases. In this initiative, Alamar’s cutting-edge NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 will play a pivotal role. These ultra-sensitive testing panels are expected to facilitate the detection of biomarkers from a vast collection of plasma samples, totaling approximately 23,000, thereby speeding up the identification of important biomarkers related to healthy aging and neurodegenerative conditions.

Prof. Monique Breteler, the head of Population Health Sciences at DZNE and the principal investigator of the Rhineland Study, emphasized the importance of detailed cohort characterization and advanced technology for understanding aging and dementia. By integrating Alamar’s multiplex panels into their research, they aim to decode molecular signatures of brain aging effectively.

The NULISAseq CNS Disease Panel 120 offers researchers the capacity to measure levels of hundreds of critical proteins that are vital for brain function using minimal blood volume. Notably, this panel can distinguish phosphorylated tau protein from the brain versus that found more generally in plasma. This represents a significant leap for early detection and risk stratification regarding neurodegenerative diseases such as Alzheimer's. Complementarily, the Inflammation Panel 250 delivers robust profiling of immune-related proteins tied to aging and neuroinflammation associated with neurodegenerative conditions.

The resultant proteomic data collected from this endeavor will be paired with extensive clinical, demographic, and imaging datasets. This integration is aimed at tracking protein changes over time, identifying early biomarkers, improving diagnostic precision, and fostering the development of targeted therapies for neurodegenerative diseases.

Dr. Yuling Luo, Founder, Chairman, and CEO of Alamar Biosciences, remarked, "This partnership marks a significant advancement in aging and dementia research. With the unparalleled sensitivity of the NULISA technology and the depth of the DZNE Rhineland Study, we can uncover new protein biomarkers that reveal trajectories of cognitive health and disease progression in the aging population."

The collaboration between Alamar Biosciences and DZNE reflects their shared commitment to scientific precision, inclusivity, and innovations in neurodegenerative disease research. By capturing the diverse aging trajectories within a meticulously mapped population, both partners are striving for earlier diagnoses, improved prognostics, and novel therapeutic pathways to address age-related brain disorders.

About the Rhineland Study

The Rhineland Study is a long-term population-based cohort study conducted by DZNE, which follows thousands of individuals for decades to uncover the determinants of healthy aging and the onset of neurodegenerative diseases. It collects and integrates detailed clinical and genetic data, imaging results, and lifestyle information to gain profound insights into aging brains.

For more information about DZNE, visit www.dzne.de/en/ and for further details about the Rhineland Study, go to www.rheinland-studie.de/en/.

About Alamar Biosciences, Inc.

Alamar Biosciences is a private life sciences company dedicated to precision proteomics for early disease detection. Its proprietary NULISA platform and ARGO HT system synergize with the latest genomic advancements, achieving detection sensitivity at the attomole level, far surpassing the most sensitive protein detection technologies currently available.

For additional information, visit alamarbio.com.